الفهرس 
IntroductionOnly 14 pages are availabe for public view
Abstract
Hepatitis C is an infectious disease caused by hepatitis C virus (HCV) which mainly attacks the liver cells.
Near eighty percent of patients develop CHC that after many years may lead to cirrhosis or liver cancer.
Egypt has the highest prevalence rate of HCV in the world. About 14.7% of the Egyptian people have HCV antibodies and 9.8% have an active infection. The death rate due to liver disease about 40,000 each year (near 10% of all deaths). It is the second after the cardiac diseases.
With the ultimate goal of achieving a more potent strategy to control transmission of HCV in Egypt, The Ministry of Health has set up 32 specialized centers for the nationwide therapy of HCV infection.
New era for management of chronic HCV using direct antiviral agents (DAAs) started in 2013.
In our study we found that HCV Core Antigen level has significantly decreased after the end of treatment and there was high significant difference between its level before and after treatment with DASS therapy.
•There is a high significant correlation between HCV RNA and HCV core antigen results, so HCV core antigen can be used as an alternative measur to HCV RNA in treatment of HCV infected chronic patients receiving Sofosbuvir, Daclatasvir.
• In our study Cut off value of HCV core antigen is less than 8 IU